VR Logo

Supernus Pharmaceuticals Inc. (SUPN) download report


Healthcare | Drugs & Pharma

Supernus Pharmaceuticals Inc. (SUPN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

IPO Date: 01-May-2012

Founder, Pres, CEO, Sec. & Director: Mr. Jack A. Khattar

Sr. VP & CFO: Mr. Timothy C. Dec

Listing: NASDAQ: SUPN

Country: United States

Headquarters: Rockville, MD

Website: https://www.supernus.com

Key Facts

Market cap: $1,482.75 Mln

Revenue (TTM): $607.89 Mln

Earnings (TTM): $50.17 Mln

Cash: $339.68 Mln

Total Debt: $446.41 Mln

Insider's Holding: 4.29%

Liquidity: Low

52 Week range: $23.15 - 34.50

Shares outstanding: 53,413,200

10 Years Aggregate:

  • CFO: $653.80 Mln
  • EBITDA: $790.34 Mln
  • Net Profit: $448.26 Mln

Stock Performance

Time Period Supernus Pharmaceuticals (SUPN) S&P BSE Healthcare S&P Small-Cap 600
YTD-2.61-17.32-17.79
1 month4.60-4.56-2.72
3 months-9.87-10.61-12.17
1 Year-11.06-12.90-15.82
3 Years-2.7219.537.14
5 Years-8.459.106.20
10 Years18.6212.4410.33
As on 24-Jun-2022
Year Supernus Pharmaceuticals (SUPN) S&P Small-Cap 600 S&P BSE Healthcare
202115.9025.2720.87
20206.079.5761.45
2019-28.6020.86-3.55
2018-16.55-9.70-5.89
201757.8211.730.49
201687.8724.74-12.88
201561.93-3.3615.06